ACRUX LIMITED — Capital/Financing Update 2009

Jun 18, 2009

ACRUX LIMITED (ACR) - ASX ANNOUNCEMENT

19 JUNE 2009

ACRUX SIGNS ELLAVIE™ DISTRIBUTION AGREEMENT FOR SWITZERLAND

Melbourne, 19 June 2009: Acrux (ASX: ACR) today announced a marketing and distribution agreement for its unique transdermal estradiol spray product Ellavie™ in Switzerland. This is the first distribution agreement for Ellavie™ in the important European market.

Ellavie™ will be marketed by Vifor Pharma, a fully integrated specialty pharmaceutical company in the Swiss-based Galenica Group. Established in 1927, Galenica operates successfully at every stage of the pharmaceutical business, from research to retailing.

Under the exclusive distribution agreement, Acrux will receive fees on signing, on confirmation of Swiss marketing authorisation and on the first three anniversaries of market launch. In addition, Acrux will receive an ongoing distribution fee based on net sales of Ellavie™. Vifor Pharma is responsible for obtaining marketing authorisation in Switzerland, utilising the product dossier previously approved by the US Food and Drug Administration (FDA). The Swiss marketing authorisation process is independent of the process in the European Union.

Ellavie™ is currently marketed in the US as Evamist™ and is under evaluation by the regulatory authorities in Australia and Sweden.

“Vifor Pharma represents a strong partner for Acrux in Switzerland, leveraging its existing women’s health franchise”, said Acrux CEO Dr Richard Treagus. “Whilst the Swiss pharmaceutical market is relatively small, sales of hormone replacement products represent a higher proportion than in many other countries. Vifor Pharma’s established market position and expertise will be valuable towards achieving rapid commercialisation.”

About Ellavie™

Ellavie™ is a small, hand-held spray, designed to provide an easy and convenient means of delivering a preset dose of estradiol via the skin, in order to reduce symptoms that affect quality of life for many menopausal women. Ellavie™ is placed gently against the skin and an actuator button is pushed, releasing a light spray containing a proprietary formulation of estradiol. The spray is fast drying, non-irritating and invisible after application. Estradiol is released into the blood stream on a sustained basis over 24 hours.

==> picture [123 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [106 x 66] intentionally omitted <==

For more information contact:

Dr Richard Treagus, CEO & Managing Director +61 417 520 509 +61 3 8379 0100

About Acrux - www.acrux.com.au

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.

• Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.

• Acrux has one product, Evamist™ (brand name Ellavie™ outside the USA) to treat menopause symptoms, marketed by its licensee in the USA and has the following products in clinical development:

  • AXIRON™ to treat testosterone deficiency in men

  • Testosterone MDTS[®] to treat decreased libido in women

  • Nestorone[®] MDTS[®] contraceptive sprays for women

  • An undisclosed companion animal health product

  • Nicotine MDTS[®] for smoking cessation

• Acrux has licensed US rights for Evamist™ to KV Pharmaceutical, US rights for Testosterone MDTS[®] to VIVUS, and distribution rights for Ellavie™ in Southern Africa and AUS/NZ to Aspen Pharmacare. Acrux has also licensed its technology to Eli Lilly and Company for veterinary healthcare products and has an exclusive alliance with Orion Corporation for commercial product supply.

About Vifor Pharma

• Vifor Pharma, the Pharma business sector of the Galenica Group, develops and manufactures prescription pharmaceutical products, with a focus on the treatment of iron deficiency, where Vifor Pharma is a world leader. Vifor Pharma also undertakes the clinical development of medications for the treatment of various autoimmune diseases. Further, Vifor Pharma manufactures prescription and OTC products that are both developed within the company and produced or sold under license, and markets them in a number of international markets. Vifor Pharma is headquartered in Switzerland (Zurich).

==> picture [123 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [106 x 66] intentionally omitted <==